Sleep Disturbances as a Non-Traditional Risk Factor in Chronic Kidney Disease- University of Illinois
CRIC
2 other identifiers
observational
89
1 country
1
Brief Summary
This study will help determine the relationship between impaired sleep and chronic kidney disease, specifically to determine if sleep disturbances are a risk factor for worsening kidney function.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2006
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2006
CompletedFirst Submitted
Initial submission to the registry
January 5, 2009
CompletedFirst Posted
Study publicly available on registry
January 6, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2011
CompletedSeptember 5, 2013
September 1, 2013
4.9 years
January 5, 2009
September 4, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Sleep Quality
Sleep Quality was determined after PSG on all subjects were completed
Study Arms (2)
1
Subjects with mild to moderate kidney disease
2
Healthy Control Subjects
Eligibility Criteria
Renal Clinic patients at The University of Illinois at Chicago Hospital
You may qualify if:
- CKD subjects will be participants in a larger study, CRIC, at the University of Illinois, Chicago
- Healthy controls age and gender matched to 30 CKD subjects, regular bedtimes of at least 6h/night, sedentary lifestyle
You may not qualify if:
- Diabetes
- Current or previous dialysis for more than 1 month
- Uncontrolled hypertension
- Heart failure
- Liver disease
- HIV
- Hemoglobin \< 10.5 g/dl
- Treatment with EProcrit, Epogen, or Aranesp
- Bone or organ transplant,
- Use of immunosuppressive drugs within past 6 months
- Current oral contraceptive use
- Current pregnancy
- Chemotherapy for malignancy within past 2 years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Chicagolead
- University of Illinois at Chicagocollaborator
Study Sites (1)
The University of Illinois at Chicago
Chicago, Illinois, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Eve Van Cauter, PhD
University of Chicago
- PRINCIPAL INVESTIGATOR
James Lash, MD
University of Illinois at Chicago
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 5, 2009
First Posted
January 6, 2009
Study Start
July 1, 2006
Primary Completion
June 1, 2011
Study Completion
June 1, 2011
Last Updated
September 5, 2013
Record last verified: 2013-09